Pioneering biotech company formed to commercialise world class research from University College London

Biovex had developed a new class of patent biologics for the treatment of cancer and infectious diseases. SEP led an international syndicate of investors to support the company with its plans to bring the world’s first cancer destroying virus to market.

Investment enabled Biovex to transition from an early UK biotech to a substantial global business, relocating to the US and establishing its own manufacturing facility in Massachusetts. In 2011 Biovex was acquired by NASDAQ listed Amgen in a $1 billion deal representing one of the world’s largest exits for a venture backed biotechnology company.

Exit date

Sign up to SEP news